IDEAYA Biosciences, Inc. IDYA IDE849 — External Clinical Development Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by IDEAYA Biosciences, Inc. in its filing.
Tagged under the XBRL concept idya:ExternalClinicalDevelopmentExpenses.
The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about IDEAYA Biosciences, Inc.'s ide849 — external clinical development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is IDEAYA Biosciences, Inc.'s IDE849 — external clinical development expenses?
- IDEAYA Biosciences, Inc. (IDYA) reported IDE849 — external clinical development expenses of $4.77M in Q1 2026.
- How has IDEAYA Biosciences, Inc.'s IDE849 — external clinical development expenses changed year-over-year?
- IDEAYA Biosciences, Inc.'s IDE849 — external clinical development expenses increased by 1026.5% year-over-year, from $423K to $4.77M.
- What does IDE849 — external clinical development expenses mean?
- This metric represents the total third-party costs incurred for the clinical advancement of a specific oncology drug candidate, including payments to contract research organizations, clinical trial sites, and laboratory services. It serves as a key indicator of the capital intensity and development velocity for a particular precision medicine program. Monitoring these expenditures helps investors assess the progress of clinical trials and the company's resource allocation toward its pipeline assets.